Zinc oxide nanoparticles induce an adverse effect on blood glucose levels depending on the dose and route of administration in healthy and diabetic rats

Adolfo Virgen-Ortiz*, Alejandro Apolinar-Iribe, Irene Díaz-Reval, Hortensia Parra-Delgado, Saraí Limón-Miranda, Enrique Alejandro Sánchez-Pastor, Luis Castro-Sánchez, Santos Jesús Castillo, Adan Dagnino-Acosta, Edgar Bonales-Alatorre, Alejandrina Rodriguez-Hernández

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Different studies in experimental diabetes models suggest that zinc oxide nanoparticles (ZnONPs) are useful as antidiabetic agents. However, this evidence was performed and measured in long-term treatments and with repeated doses of ZnONPs. This work aimed to evaluate the ZnONPs acute effects on glycemia during the next six h after an oral or intraperitoneal administration of the treatment in healthy and diabetic rats. In this study, the streptozotocin-nicotinamide intraperitoneal administration in male Wistar rats were used as a diabetes model. 10 mg/kg ZnONPs did not modify the baseline glucose in any group. Nevertheless, the ZnONPs short-term administration (100 mg/kg) induced a hyperglycemic response in a dose and route-dependent administration in healthy (130 ± 2 and 165 ± 10 mg/dL with oral and intraperitoneal, respectively) and diabetic rats (155 ± 2 and 240 ± 20 mg/dL with oral, and intraperitoneal, respectively). The diabetic rats were 1.5 fold more sensitive to ZnONPs effect by the intraperitoneal route. In conclusion, this study provides new information about the acute response of ZnONPs on fasting glycemia in diabetic and healthy rat models; these data are essential for possible future clinical approaches.

Original languageEnglish
Article number2005
Pages (from-to)1-10
Number of pages10
JournalNanomaterials
Volume10
Issue number10
DOIs
StatePublished - Oct 2020

Bibliographical note

Funding Information:
Funding: This research was funded by Centro Universitario de Investigaciones Biomédicas, Universidad de Colima. The APC was funded by all authors.

Funding Information:
This research was funded by Centro Universitario de Investigaciones Biomedicas, Universidad de Colima. The APC was funded by all authors.

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

  • Diabetes
  • Hyperglycemic response
  • Nanomedicine
  • Nanoparticle toxicology
  • Zinc
  • Zinc oxide nanoparticles

Fingerprint

Dive into the research topics of 'Zinc oxide nanoparticles induce an adverse effect on blood glucose levels depending on the dose and route of administration in healthy and diabetic rats'. Together they form a unique fingerprint.

Cite this